Among the two patients who received R-chemotherapy, one (MC4) gained additional mutations (SELENBP1) in relapse based on pretreatment dominant tumor clones, whereas the other (MC206) acquired mutations (CD70 and ZFP36L1) from a minor and undetected pretreatment tumor clone. Here, SELENBP1 is linked to neoplasm.